Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) Director Jean Formela sold 40,045 shares of the company’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $14.30, for a total value of $572,643.50. Following the sale, the director owned 121,219 shares of the company’s stock, valued at approximately $1,733,431.70. This trade represents a 24.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jean Francois Formela also recently made the following trade(s):
- On Wednesday, November 11th, Jean Formela sold 26,587 shares of Korro Bio stock. The stock was sold at an average price of $15.08, for a total value of $400,931.96.
- On Wednesday, August 26th, Jean Formela sold 300 shares of Korro Bio stock. The stock was sold at an average price of $13.96, for a total value of $4,188.00.
- On Wednesday, August 19th, Jean Formela sold 28,468 shares of Korro Bio stock. The stock was sold at an average price of $14.00, for a total value of $398,552.00.
Korro Bio Price Performance
Shares of KRRO stock opened at $13.61 on Monday. Korro Bio, Inc. has a 12 month low of $5.20 and a 12 month high of $17.35. The business’s 50 day moving average is $11.86 and its two-hundred day moving average is $12.16. The company has a market cap of $186.87 million, a PE ratio of -1.50 and a beta of 3.23.
Korro Bio (NASDAQ:KRRO – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.16. As a group, equities analysts expect that Korro Bio, Inc. will post -4.45 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
KRRO has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Korro Bio from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Jefferies Financial Group set a $15.00 price target on shares of Korro Bio in a report on Tuesday, October 6th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Korro Bio in a research report on Tuesday, October 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Korro Bio in a research report on Friday, October 2nd. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $17.29.
Get Our Latest Analysis on KRRO
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of KRRO. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Korro Bio in the third quarter worth $54,000. North Star Investment Management Corp. increased its position in Korro Bio by 1,044.4% during the third quarter. North Star Investment Management Corp. now owns 20,600 shares of the company’s stock worth $204,000 after acquiring an additional 18,800 shares during the period. Deutsche Bank AG bought a new position in Korro Bio during the second quarter worth $210,000. Hsbc Holdings PLC acquired a new position in Korro Bio during the 2nd quarter valued at $233,000. Finally, Bank of New York Mellon Corp raised its stake in Korro Bio by 15.2% during the 1st quarter. Bank of New York Mellon Corp now owns 21,730 shares of the company’s stock valued at $246,000 after purchasing an additional 2,875 shares during the last quarter. 13.18% of the stock is currently owned by institutional investors and hedge funds.
About Korro Bio
Korro Bio is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. It develops RNA-editing medicines intended to address genetic diseases by changing specific RNA sequences rather than altering a patient’s DNA. The company’s OPERA platform uses oligonucleotides to direct the body’s naturally occurring ADAR enzymes to edit targeted RNA. Korro has developed KRRO-110, an investigational candidate designed to correct a disease-associated RNA change linked to alpha-1 antitrypsin deficiency.
Featured Articles
- Five stocks we like better than Korro Bio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.
